Nanohale AG acquires R&D and service units of Scil Technology GmbH

Nanohale AG and Scil Technology GmbH  has announced that Nanohale has acquired the entire R&D, contract development and manufacturing organization of Scil Technology GmbH in an asset deal, effective December 31, 2011.

Employees and inventory of Scil Technology GmbH have become part of Formycon GmbH, a fully-owned subsidiary of Nanohale AG. The rights to the tissue regeneration projects, which were out-licensed by Scil Technology to Medtronic, Inc. and Sanofi, will remain with Scil Technology GmbH, which will be sustained as an independent company to manage its existing collaborations. Financial details have not been disclosed. The team at Raupach & Wollert-Elmendorff  (“Raupach”) representing Scil Technology GmbH (“Scil”) in this transaction was led by Peter Homberg (pictured), partner and head of the Frankfurt office. Other team members were Dr. Stefanie Greifeneder, Senior Associate, and Andrea Veh, Associate.

This was the second transaction for Scil within a few month time. However, Raupach has a longstanding relationship with BioNet Holding, the shareholder of Scil.This transaction comprises the sale of Scil’s research and development department as well as the capacities for contract manufacturing to Nanohale. The parties have agreed not to disclose any financial details of the transaction.